Aldeyra Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow $ALDX Shareholders to Recover Losses

Core Viewpoint - Aldeyra Therapeutics, Inc. has faced a significant decline in its stock price, dropping over 65% after receiving a Complete Response Letter from the FDA regarding its drug reproxalap for dry eye disease, indicating a failure to demonstrate efficacy in clinical trials [2]. Company Overview - Aldeyra Therapeutics, Inc. is under investigation by Block & Leviton for potential securities law violations following the FDA's response regarding reproxalap [1][4]. - The company previously disclosed that the FDA required at least one additional adequate and well-controlled study to demonstrate the drug's effectiveness [2]. Investor Information - Investors who purchased Aldeyra Therapeutics common stock and experienced a loss may be eligible to recover losses through Block & Leviton's investigation [3]. - Block & Leviton is known for representing defrauded investors and has recovered billions of dollars through litigation [7]. Legal Actions - Block & Leviton is considering filing an action to recover losses on behalf of affected investors [4]. - Whistleblowers with non-public information about Aldeyra Therapeutics are encouraged to assist in the investigation, with potential rewards for original information provided to the SEC [6].